Nanocis (Rhenium Sulfide)

Rhenium sulfide, the active ingredient in Nanocis, is a compound presented as a pharmaceutical preparation for oral and subcutaneous use. It is being investigated for potential therapeutic applications in experimental settings.

GNH USA supplies Nanocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanocis (Rhenium sulfide) is currently under clinical investigation and no approved therapeutic indications have been established.

Common Side Effects: - None reported in publicly available clinical data. - Mild injection site irritation (when administered subcutaneously). - Transient gastrointestinal discomfort (when taken orally).

Serious or Rare Side Effects: - Hypersensitivity reactions, including rash or anaphylaxis. - Potential organ toxicity that has not been fully characterized. - Unexplained hematologic abnormalities. - Severe electrolyte disturbances. - Rare neurologic symptoms such as dizziness or headache.

Nanocis should be used only under the supervision of a qualified healthcare professional. - Pregnancy: Avoid use unless clearly needed; safety data are insufficient. - Breastfeeding: Discontinue use as the compound may be excreted in milk. - Renal impairment: Monitor kidney function closely. - Hepatic impairment: Use with caution and monitor liver enzymes. - Immunocompromised patients: Assess risk of infection. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Nanocis may interact with other agents that affect redox balance or metal homeostasis.

Major Interactions (Avoid): - Strong oxidizing agents: may increase toxicity. - Chelating agents (e.g., deferoxamine): could reduce efficacy. - Immunosuppressants: potential additive immunomodulation.

Moderate Interactions (Monitor Closely): - Antioxidant supplements (vitamin C, E): may alter pharmacodynamics. - Certain antibiotics (e.g., fluoroquinolones): possible synergistic toxicity. - Hormonal therapies: monitor for unexpected endocrine effects.